1. Home
  2. LPLA vs CADL Comparison

LPLA vs CADL Comparison

Compare LPLA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPLA
  • CADL
  • Stock Information
  • Founded
  • LPLA 1989
  • CADL 1999
  • Country
  • LPLA United States
  • CADL United States
  • Employees
  • LPLA N/A
  • CADL N/A
  • Industry
  • LPLA Investment Bankers/Brokers/Service
  • CADL Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPLA Finance
  • CADL Health Care
  • Exchange
  • LPLA Nasdaq
  • CADL Nasdaq
  • Market Cap
  • LPLA N/A
  • CADL 185.2M
  • IPO Year
  • LPLA 2010
  • CADL 2021
  • Fundamental
  • Price
  • LPLA $211.62
  • CADL $6.20
  • Analyst Decision
  • LPLA Buy
  • CADL Strong Buy
  • Analyst Count
  • LPLA 12
  • CADL 1
  • Target Price
  • LPLA $287.27
  • CADL $11.00
  • AVG Volume (30 Days)
  • LPLA 1.1M
  • CADL 599.6K
  • Earning Date
  • LPLA 07-25-2024
  • CADL 08-08-2024
  • Dividend Yield
  • LPLA 0.58%
  • CADL N/A
  • EPS Growth
  • LPLA 2.00
  • CADL N/A
  • EPS
  • LPLA 13.26
  • CADL N/A
  • Revenue
  • LPLA $10,467,609,000.00
  • CADL N/A
  • Revenue This Year
  • LPLA $18.97
  • CADL N/A
  • Revenue Next Year
  • LPLA $15.62
  • CADL N/A
  • P/E Ratio
  • LPLA $15.89
  • CADL N/A
  • Revenue Growth
  • LPLA 16.92
  • CADL N/A
  • 52 Week Low
  • LPLA $200.18
  • CADL $0.66
  • 52 Week High
  • LPLA $289.88
  • CADL $14.30
  • Technical
  • Relative Strength Index (RSI)
  • LPLA 11.82
  • CADL 45.08
  • Support Level
  • LPLA $262.64
  • CADL $5.75
  • Resistance Level
  • LPLA $284.59
  • CADL $7.34
  • Average True Range (ATR)
  • LPLA 10.40
  • CADL 0.50
  • MACD
  • LPLA -7.06
  • CADL 0.12
  • Stochastic Oscillator
  • LPLA 11.28
  • CADL 33.47

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: